Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-006131
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-01-31 08:39:40
Reporting Period:
2018-01-23
Accepted Time:
2018-01-31 08:39:40
Original Submission Date:
2018-01-23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1439222 Agios Pharmaceuticals Inc AGIO Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
816284 Celgene Corp /de/ 86 Morris Avenue
Summit NJ 07901
No No Yes No
1577650 Celgene European Investment Co Llc 86 Morris Avenue
Summit NJ 07901
No No Yes No
1581774 Celgene Alpine Investment Co., Llc 86 Morris Avenue
Summit NJ 07901
No No Yes No
1661486 Celgene Switzerland Llc Aon House
30 Woodbourne Avenue
Pembroke D0 HM 08
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-23 851,154 $67.00 1,374,599 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 5,343,834 Indirect See footnote
Footnotes
  1. This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018.
  2. Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC, 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC, and 4,010,926 shares are owned directly by Celgene European Investment Company LLC, each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.